ApprovalTrail

Approval · Notice of Compliance 30703 · 2023

FULPHILA: Notice of Compliance 30703

Issued May 11, 2023

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
30703
Date
May 11, 2023
Company
BGP Pharma ULCEtobicoke, Ontario, Canada
Product type
Biologic
Submission
Supplement to a New Drug Submission (SNDS), supplement
Submission class
Other
Reason
Change in the drug product manufacturing process
Canadian reference product
NEULASTA

Products in this notice

BrandDINStatus today
FULPHILANot yet assigned—

Medicinal ingredients